A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer
Status:
Completed
Trial end date:
2000-11-01
Target enrollment:
Participant gender:
Summary
This is a pilot, chemoprevention study. Patients receive fenretinide daily for 25 of every 28
days for 4 months and tamoxifen daily for 23 months, beginning the second month of
fenretinide.
Patients are removed from study for unacceptable toxicity, the development of invasive breast
cancer, or for dysfunctional uterine bleeding.